- Home
- IKNA
IKNA
Ikena Oncology Inc.
as 11-22-2024 4:00pm EST
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 80.8M | IPO Year: | 2021 |
| Target Price: | $3.00 | AVG Volume (30 days): | 60.6K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.24 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.22 - $2.32 | Next Earning Date: | 11-07-2024 |
| Revenue: | $659,000 | Revenue Growth: | -95.28% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Ikena Oncology Inc. News
IKNA Breaking Stock News: Dive into IKNA Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
3 US Penny Stocks With Market Caps Over $40M To Consider
Simply Wall St.
14 days ago
Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023)
GlobeNewswire
16 days ago
Ikena Oncology Reports Third Quarter 2024 Financial Results
GlobeNewswire
3 months ago
Ikena Oncology Reports Second Quarter 2024 Financial Results
Zacks
4 months ago
Best Momentum Stocks to Buy for July 12th
Business Wire
5 months ago
Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition
GlobeNewswire
5 months ago
Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus
GlobeNewswire
5 months ago
Share buy-back programme - week 23
Compare IKNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IKNA Ikena Oncology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.